secwatch.observer — SEC 8-K summary
======================================

Issuer:     VivoSim Labs, INC. (VIVS)
CIK:        0001497253
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0000950170-24-011954
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organovo presents FXR314 data in 3D models of Crohn's disease and ulcerative colitis
--------------------------------------------------------------------------------

- FXR314, a clinical-stage FXR agonist, tested in human primary cell 3D models.
- Data presented at Crohn's & Colitis Congress, Jan 25-27, 2024 in Las Vegas.
- Presentation covers models for both Crohn's disease and ulcerative colitis.
- Presentation current as of January 25, 2024; furnished as Exhibit 99.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497253/000095017024011954/0000950170-24-011954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497253/000095017024011954/onvo-20240207.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-011954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer